← Back to Search


Platelet Rich Plasma Treatment for Male Infertility

Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 3 months after prp injection
Awards & highlights


This trial is investigating whether a platelet-rich plasma injection into the testicles could improve sperm retrieval rates and IVF outcomes in men who have had a failed sperm retrieval.

Who is the study for?
This trial is for men over 18 with nonobstructive azoospermia (NOA) who have had an unsuccessful testicular sperm extraction (TESE). It's aimed at those seeking new options after traditional fertility treatments haven't worked.Check my eligibility
What is being tested?
The study tests whether injecting platelet rich plasma (PRP) directly into the testes can increase the chances of finding sperm during a repeat TESE and improve in vitro fertilization (IVF) results for these men.See study design
What are the potential side effects?
Potential side effects may include discomfort, swelling, or bruising at the injection site. There could also be risks associated with needle insertion into the testicles, such as infection or damage to the tissue.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months after prp injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months after prp injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
sperm present

Trial Design

1Treatment groups
Experimental Treatment
Group I: Platelet rich plasma treatment armExperimental Treatment1 Intervention
After consent in obtained, the patient will undergo a blood draw (12 tsp) to prepare the PRP infusion. The use of a centrifuge and an Arteriocyte Magellan kit are necessary for the PRP preparation. After injection of local anesthesia, PRP will be injected into each testicle.
First Studied
Drug Approval Stage
How many patients have taken this drug
Platelet rich plasma
Completed Phase 4

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for male infertility, such as autologous platelet-rich plasma (PRP) injections, work by releasing growth factors and cytokines to promote tissue repair and regeneration in the testes, thereby improving sperm quality and function. Other treatments, like Mucuna pruriens seed powder, reactivate enzymatic activity and balance reproductive hormones, while empiric therapies with gonadotropins, antiestrogens, and antioxidants enhance seminal parameters and increase pregnancy rates. These treatments are vital for male infertility patients as they address hormonal imbalances, oxidative stress, and tissue damage, improving the likelihood of successful conception.
Plasma-Rich in Growth Factors Ameliorates Detrimental Effects of Cryopreservation on Human Sperm: A Prospective Study.Effect of platelet-rich plasma (PRP) on post-thaw quality, kinematics and in vivo fertility of fertile and subfertile buffalo (Bubalus bubalis) spermatozoa.Comparative Effect of Photobiomodulation on Human Semen Samples Pre- and Post-Cryopreservation.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,411 Previous Clinical Trials
17,462,929 Total Patients Enrolled

Media Library

Platelet Rich Plasma (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05479474 — N/A
Male Infertility Research Study Groups: Platelet rich plasma treatment arm
Male Infertility Clinical Trial 2023: Platelet Rich Plasma Highlights & Side Effects. Trial Name: NCT05479474 — N/A
Platelet Rich Plasma (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05479474 — N/A
Male Infertility Patient Testimony for trial: Trial Name: NCT05479474 — N/A
~2 spots leftby Jan 2025